AACP
TGTX icon

Advantage Alpha Capital Partners’s TG Therapeutics TGTX Stock Holding History

Advantage Alpha Capital Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,598
Closed -$419K – 110
2025
Q3 		$419K Sell
11,598
-2,716
-19% -$89.5K 0.13% 109
2025
Q2 		$515K Sell
14,314
-6,274
-30% -$234K 0.14% 98
2025
Q1 		$812K Buy
20,588
+7,141
+53% +$240K 0.2% 89
2024
Q4 		$405K Sell
13,447
-8,932
-40% -$256K 0.1% 137
2024
Q3 		$523K Sell
22,379
-11,651
-34% -$254K 0.12% 109
2024
Q2 		$605K Buy
+34,030
New +$543K 0.13% 96

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Advantage Alpha Capital Partners's TGTX Position: Q4 2025 in Review

Advantage Alpha Capital Partners sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 11,598 shares — an estimated $419K sold.

Advantage Alpha Capital Partners first reported a position in TGTX in Q2 2024 and held it in 6 quarters. The position peaked at $812K in Q1 2025. 351 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • Advantage Alpha Capital Partners reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 11,598 TG Therapeutics shares in Q4 2025, an estimated $419K.
  • Advantage Alpha Capital Partners first reported a position in TG Therapeutics in Q2 2024 and held it in 6 quarters.
  • Advantage Alpha Capital Partners's TG Therapeutics position peaked at $812K in Q1 2025.
  • 351 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2025.